The clinical implications of antitumor immunity in head and neck cancer.

PubWeight™: 0.89‹?›

🔗 View Article (PMID 22183634)

Published in Laryngoscope on January 01, 2012

Authors

Clint T Allen1, Nancy P Judd, Jack D Bui, Ravindra Uppaluri

Author Affiliations

1: Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Articles citing this

The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer (2013) 1.30

Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers (Basel) (2015) 0.90

Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. Head Neck Oncol (2013) 0.86

A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol Immunother (2014) 0.84

Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol (2015) 0.81

Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma. Neoplasia (2013) 0.80

Expression of CXCL10 is associated with response to radiotherapy and overall survival in squamous cell carcinoma of the tongue. Tumour Biol (2014) 0.80

Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma. Virchows Arch (2012) 0.79

Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. Eur J Cancer (2017) 0.75

Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol (2016) 0.75

Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. Oral Oncol (2016) 0.75

Canertinib induces ototoxicity in three preclinical models. Hear Res (2015) 0.75

Effects of omega-3 fatty acids on regulatory T cells in hematologic neoplasms. Rev Bras Hematol Hemoter (2013) 0.75

Articles by these authors

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76

A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 4.14

Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med (2012) 1.93

Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res (2006) 1.39

IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation. J Immunol (2002) 1.36

ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res (2011) 1.34

Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res (2010) 1.31

Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA. J Immunol (2009) 1.30

CD44 deficiency leads to enhanced neutrophil migration and lung injury in Escherichia coli pneumonia in mice. Am J Pathol (2002) 1.28

Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation (2008) 1.22

The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. J Immunol (2009) 1.04

Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A (2013) 0.99

Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. Cancer Res (2012) 0.92

Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci U S A (2014) 0.91

Cancer immunoediting of the NK group 2D ligand H60a. J Immunol (2011) 0.89

CXCR3 enhances a T-cell-dependent epidermal proliferative response and promotes skin tumorigenesis. Cancer Res (2011) 0.88

Identifying the initiating events of anti-Listeria responses using mice with conditional loss of IFN-γ receptor subunit 1 (IFNGR1). J Immunol (2013) 0.88

Cancer immunosurveillance and immunoediting by natural killer cells. Cancer J (2013) 0.86

Emerging insights into head and neck cancer metastasis. Head Neck (2012) 0.86

Association of reflux with otitis media in children. Otolaryngol Head Neck Surg (2005) 0.84

Spontaneous regression of cutaneous head and neck melanoma: implications for the immunologic control of neoplasia. Head Neck (2008) 0.83

Studies of the H60a locus in C57BL/6 and 129/Sv mouse strains identify the H60a 3'UTR as a regulator of H60a expression. Mol Immunol (2010) 0.83

Active Ca2+/calmodulin-dependent protein kinase II gamma B impairs positive selection of T cells by modulating TCR signaling. J Immunol (2005) 0.81

Mycotic pseudoaneurysm of the internal maxillary artery: case report and review of the literature. Arch Otolaryngol Head Neck Surg (2007) 0.79

Novel application of the palatal island flap for endoscopic skull base reconstruction. Laryngoscope (2009) 0.78

A dual function of NKG2D ligands in NK-cell activation. Eur J Immunol (2012) 0.78

Endoscopic surgical management of vidian nerve schwannoma. Laryngoscope (2011) 0.78

Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer. Otolaryngol Head Neck Surg (2012) 0.78

Combined high-field intraoperative magnetic resonance imaging and endoscopy increase extent of resection and progression-free survival for pituitary adenomas. Pituitary (2015) 0.77

Studies on the antigenicity of the NKG2D ligand H60a in tumour cells. Immunology (2011) 0.76

Effective long-term immunosuppression in rats by subcutaneously implanted sustained-release tacrolimus pellet: effect on spinally grafted human neural precursor survival. Exp Neurol (2013) 0.76

The nuclear factor-κB pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor-κB inhibitors in cancer therapy. Immunology (2013) 0.75

Pathology quiz case 2. Atypical meningioma with clear cell features (World Health Organization [WHO] grade II). Arch Otolaryngol Head Neck Surg (2008) 0.75

Juvenile xanthogranuloma of supra-sellar region: a rare presentation. Clin Neuropathol (2015) 0.75